

# Evaluation of the efficacy and safety of elemene in treating malignant pleural effusion caused by tumors

## A PRISMA guided meta-analysis

Qing-tao Wang, MM, Ze-lin Zhang, MB, Hui Xiong, MB<sup>\*</sup>, Dong-sheng Zhou, MB, Jun Li, MM, Jian Liang, MM, Ya-fei Wang, MM

#### Abstract

**Objective:** Elemene is widely used to treat malignant pleural effusion in China. This meta-analysis aimed to evaluate the efficacy and safety of elemene in treating malignant pleural effusion.

**Methods:** Electronic databases including Pubmed, the Cochrane Library, Embase and Chinese biomedical literature database were searched until March 2017. Clinical controlled trials (CCTs) assessing the efficacy and safety of elemene in the treatment of malignant pleural effusion were included. The quality of the included studies was evaluated using the quality evaluation criteria of the Cochrane Handbook version 5.1.0.

**Results:** A total of 46 CCTs were included, with 2992 patients. Results of meta-analysis showed that elemene significantly improved the overall response rate (ORR) in controlling malignant pleural effusion (risk ratio [RR] = 1.16; 95% CI: 1.08–1.23; P < .05). Subgroup results showed that the ORR of elemene in the treatment of lung cancer patients with malignant pleural effusion (RR = 1.20, 95% CI: 1.07–1.34; P < .05) was higher than that of other cancers (RR = 1.14, 95% CI: 1.05–1.23; P < .05). Meanwhile, elemene did not significantly increase the incidences of chest pain and fever (P > .05).

**Conclusion:** Elemene is suggested to have the ability of improving the treatment outcome of malignant pleural effusion with acceptable safety.

**Abbreviations:** BLM = bleomycin, CBM = Chinese Biomedical Literature Database, CCTs = clinical controlled trials, CI = confidence interval, CR = complete response, DDP = cisplatin, OR = odds ratio, ORR = overall response rate, PR = partial response, QOL = quality of life, RCTs = randomized controlled trials, RR = risk ratio.

Keywords: cancer, elemene, malignant pleural effusion, meta-analysis, traditional Chinese medicine ;

#### 1. Introduction

Malignant pleural effusion is often diagnosed based on aggressive pleural effusion or pleural biopsy.<sup>[1]</sup> The occurrence of malignant pleural effusion is almost associated with advanced malignant tumors, affecting quality of life (QOL) and representing high mortality.<sup>[2,3]</sup> Massive pleural effusions may occasionally cause significant lung mediastinal compression, resulting in respiratory and circulatory failure, which often need emergency treatments.<sup>[2,3]</sup>

The authors have no conflicts of interest to disclose.

Received: 16 April 2018 / Accepted: 31 August 2018 http://dx.doi.org/10.1097/MD.000000000012542 The characteristics mentioned above suggest a palliative treatment regimen, as the survival of these patients ranges from 4 months to 1 year, despite considerable advances achieved in recent years.<sup>[2,3]</sup> Recurrence of malignant pleural effusions is common following initial thoracentesis. Besides, repeated extraction of pleural effusion will accelerate the loss of albumin and cause electrolyte imbalance in cancer patients.<sup>[4,5]</sup> Therefore, effective control of malignant pleural effusion can improve the general condition of patients, and thus it is the main focus of therapy for advanced cancer patients with malignant pleural effusion.<sup>[6]</sup> At present, the commonly used clinical treatment of malignant pleural effusion includes systemic chemotherapy, diuretic, and thoracic injection of drugs (such as cisplatin (DDP), bleomycin [BLM] and traditional Chinese medicine preparations) for pleurodesis after thoracic closed drainage.<sup>[6,7]</sup>

Elemene, 1 of the Chinese medicine extracts, is extracted from the ginger plant temperature turmeric, exhibiting anti-cancer activity.<sup>[8]</sup> According to the drug instruction of Elemene Injection, it contains a mixture of  $\beta$ -, $\gamma$ -, and  $\delta$ -Elemene. Basic and clinical experimental results showed that elemene has a wide range of anti-tumor spectrum, with curative effect, mild adverse reactions and other prominent advantages.<sup>[8–10]</sup> In recent years, there have been several reports of elemene alone or combined with chemotherapy and/or hyperthermia in the treatment of malignant pleural effusion, however, the results are not entirely consistent.<sup>[8,11]</sup> In 2014, Chen et al performed a meta-analysis to evaluate the clinical efficacy of elemene intrapleural injection in

Editor: Muhammad Shahzad Aslam.

QW and ZZ contribute equally.

Supplemental Digital Content is available for this article.

Department of Cardiothoracic and Breast Surgery, Xiang Yang No. 1 People's Hospital, HuBei University of Medicine, XiangYang, Hubei, P.R. China.

<sup>&</sup>lt;sup>\*</sup> Correspondence: Hui Xiong, Jiefang Road #75, Fancheng District, Xiangyang, Hubei, 441000, P.R. China (e-mail: zxhua.008@163.com).

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

Medicine (2018) 97:44(e12542)

lung cancer patients with malignant pleural effusion.<sup>[8]</sup> Two years later, Wang et al conducted another meta-analysis to evaluate the clinical efficacy of elemene versus DDP in treating malignant pleural effusion caused by lung cancer.<sup>[12]</sup> These 2 meta-analyses only included lung cancer patients with malignant pleural effusion. In addition, elemene was mainly compared with DDP in limited number of clinical trials. However, whether elemene versus other controls has the similar efficacy and safety in the treatment of pleural effusion caused by lung cancer or other cancers, there is lack of sufficient evidence.

In this study, we searched the electronic databases including PubMed, the Cochrane library, EMbase, and Chinese Biomedical Literature Database (CBM), screened the eligible randomized controlled trials (RCTs), extracted data of efficacy and safety, and conducted this meta-analysis to assess the efficacy and safety of elemene versus other controls in treating malignant pleural effusion caused by several different types of cancers, aiming to provide evidence-based medicine for application of elemene.

#### 2. Methods

This study was performed under the guideline of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). This study was not registered.

#### 2.1. Search strategy

Electronic databases including PubMed, the Cochrane library, EMbase, and CBM were searched to identify clinical controlled trials (CCTs) comparing the efficacy and safety of elemene versus other agents in treating malignant pleural effusion. Relevant literatures indicated by the initial reference on the same topic were also searched. The search period was from the establishment of the database to March 2017. The language of the references was limited to Chinese or English. The search terms used in various combinations were as follows: elemene, elemenum emulsion, delta-elemene, elemene injection, chemotherapy, DDP, BLM, tumor pleural effusion, cancer pleural effusion, and malignant pleural effusion.

#### 2.2. Inclusion and exclusion criteria

Subjects: patients with malignant pleural effusion diagnosed by pathology or cytology. Study types: CCT presenting adequate definition of efficacy (such as complete response (CR), partial response (PR) and overall response rate [ORR]), adverse events and evaluating the efficacy and safety of elemene alone or combined with DDP or BLM or hyperthermia versus DDP or BLM or hyperthermia in the treatment of malignant pleural effusions. Interventions: experimental group used elemene based regimen, the control group used elemene free regimen. Exclusion criteria:

- (1) non-malignant pleural effusion;
- (2) incomplete or insufficient data of efficacy and safety;
- (3) reviews and animal studies.

This study did not need ethical approval as it was a metaanalysis. All the grades of disease described in our included studies are advanced disease. The concentration of elemene was 0.1 g/20mL (5 mg/mL) as stated in the drug instruction of elemene.

#### 2.3. Endpoints

Primary endpoints were CR rate, PR rate and ORR. As mentioned above, there were adequate definitions of the primary

endpoints in the eligible studies. Secondary endpoints included adverse events and QOL.

#### 2.4. Screening for eligible CCTs and data extraction

The processes of screening and identifying the potential literature and filling the designed form were done by 2 reviewers, independently. When it is uncertain about data or study, a third reviewer was employed. If the interested information was incomplete, the authors of the original publications were contacted to obtain essential data. Otherwise, the article was dropped. The basic characteristics of the studies including title, publication year, primary diseases, diagnosis of malignant pleural effusion, number of the patients, age of the patients, the time of follow-up, and interventions were extracted by 2 reviewers, independently. The outcomes of the included studies, such as CR, PR, ORR, QOL and safety of elemene versus other medications were also extracted and used for the meta-analysis.

#### 2.5. Quality assessment of included studies

The quality of the included studies was evaluated according to the Cochrane Handbook 5.1.<sup>[13]</sup> The evaluated items are mainly as following:

- randomization: it contains 3 categories: correct and adequate, inadequate, and not clear, based on whether random methods are used and their use is reasonable;
- (2) allocation concealment: it has 4 categories: correct and sufficient, inadequate, unclear, and not used;
- (3) blinding: it can be divided into single blind, double blind, and triple blind according to whether the blind is rationally used;
- (4) loss to follow-up;
- (5) incomplete reporting;
- (6) selective reporting;
- (7) other sources of biases.

The quality of the studies can be divided into three degrees. Grade A: mild bias with full compliance with the above quality standards, and smallest possibility of various bias. Grade B stands for moderate bias. It is defined as only 1 or more of the criteria are fulfilled, and the probability of occurrence of bias is moderate. Grade C means high bias. It is defined as completely unsatisfied with any 1 or more of the standards, with the highest probability of bias.

#### 2.6. Statistical analysis

Meta-analysis was performed using the stata 12.0 software. The RR and its 95% confidence interval (CI) were used to represent the overall effect of the combined data. The weighted mean difference (WMD) and its 95% CI were used to represent the pooled effect of continuous variable. The heterogeneity between the included studies was analyzed by Cochran Q statistic and the I<sup>2</sup> statistic (0.25, 0.50, and 0.75 suggesting low, moderate, and high degrees of heterogeneity, respectively). When P < .05 and  $I^2 > 50\%$ , the random effect model was used for meta-analysis. Otherwise, the fixed effect model was used for analysis. The bias of publication was assessed by the Egger regression asymmetry test and the funnel plot. If there was no clinical homogeneity between the studies, the sub-group analysis was introduced. It was considered as statistically significant when the P < .05.

#### 3. Results

#### 3.1. Search results

A total of 1820 relevant articles were obtained after primary search. After reading the title and abstract, the literatures that did not meet the inclusion criteria were excluded, and 122 articles left. After further reviewing of the full text, studies with interventions, subjects, or other aspects that did not meet the inclusion criteria were excluded, resulting in 46 clinical trials.<sup>[11,14–58]</sup> 2992 cancer patients were included, 1499 of them were in the elemene group, and the rest were in the control group. The baseline data of the 2 groups were comparable. The specific process of searching and identifying the literatures is shown in Figure 1.

#### 3.2. Baseline characteristics and overall quality of included studies

In summary, 89% were RCTs and the rest was retrospective trials (Table 1). The age of patients participated in these studies

ranged from 18 to 82 years. This population was diagnosed with advanced cancers. The primary diseases were lung cancer, breast cancer, gastric cancer, ovarian cancer and other types of malignant tumors. The diagnostic methods of malignant pleural effusion included B-ultrasound, computed tomography scan, Magnetic Resonance Imaging scan, and effusion extraction. Elemene, DDP, BLM, interleukin-2 (IL-2), and other medications were used as interventions for these cases. The duration and dose of elemene varied across included trials, with a range of 200 mg/m<sup>2</sup> to 300 mg/m<sup>2</sup>, q.w., for 2 W to 3 W. The reported outcomes were mainly focused on efficacy of controlling malignant pleural effusion, improving QOL, and incidences of adverse events.

The quality of included studies was assessed according to the Cochrane Handbook 5.1. Overall, the quality of these trials was considered as moderate risk of bias. Though most of the studies reported utilization of randomization, the specific details and methods of randomization were presented in only few trials. Risk of allocation was evaluated as moderate to




Figure 1. Study flow diagram.

# Table 1 Baseline characteristics of included studies.

	_	Ν	S	ex	A	ge	Interve	ntions		
Studies	Т	C	М	F	T	C	Т	C	Cancers	Outcomes
Fang Zhao,et al 2015	17	17	17	17	42-75	42-75	Elemene 300 mg, QW,	bleomycin 45 mg, QW,	Lung cancer	Efficacy, AEs
Jingbo Sun, et al 2014	15	15	20	10	24–80	23–79	3W Elemene, 400mg, QW, 2W	3W DDP 60mg, QW, 2W	Lung cancer, breast cancer and other cancers	Efficacy
Jianpeng Li, et al 2014	40	41	NA	NA	60–82	60-82	Elemene 200 mg/m <sup>2</sup> in 40 ml saline + IL-2 2MU,	DDP 40 mg/m <sup>2</sup> , IL-2 2MU, QW, 3W	Lung cancer, breast cancer and other cancers	Efficacy, AEs, QOL
Jinna Wang, et al 2015	40	40	45	35	34–70	33–71	QW, 3W elemene 300mg/m <sup>2</sup> , QW, 2W	DDP 40-60 mg, QW, 2W	Lung cancer	Efficacy
Bianrong Wu, et al 2015	29	27	31	25	42–76	45–78	Elemene 400 mg, QW, 3W	DDP80 mg, QW, 3W	Lung cancer	Efficacy, AEs,
/ihe Zhang, et al 2016	32	31	27	36	55.5	56	Elemene 200mg/m <sup>2</sup> , QW, 3W	epirubicin 50mg/m <sup>2</sup> , QW, 3W	Lung cancer, breast cancer and other cancers	QOL Efficacy, AEs
Jing Su, et al 2014	23	22	25	20	29–74	30–75	Elemene 200 mg in 40 ml	DDP 40 mg/m <sup>2</sup> , QW,	Lung cancer, breast cancer	Efficacy
Ke Dong, et al 2015	35	35	41	29	$54.6 \pm 4.5$	$55.2 \pm 4.4$	Saline, QW, 3W Elemen, 600 mg, DDP40mg/m <sup>2</sup> , QW	3W DDP40mg/m <sup>2</sup> , QW	and other cancers Lung cancer	Efficacy, AEs
Zhuangwei Li, et al 2016	30	30	35	25	38–70	40-70	Elemene 400 mg in 250 ml saline + IL-2	Elemene 400 mg in 250 ml saline	Lung cancer, breast cancer and other cancers	Efficacy, AEs
Zan Liu, et al 2016	26	26	32	20	34–78	34–78	Elemene 200mg/m <sup>2</sup> + DDP40mg/m <sup>2</sup> + Fluorouracil 750mg/m <sup>2</sup> , QW	DDP 40 mg/m <sup>2</sup> + Fluorouracil 750 mg/ m <sup>2</sup> , QW	Lung cancer, breast cancer and other cancers	Efficacy, KPS
Hong Wang, et al 2007 Zhihong Feng, et al 2015	32 40	41 40	41 37	32 43	38–78 35–70	34–76 35–72	Elemene 300 mg IL-2 2MU + elemene 300 mg, QW, 3W	bleomycin 45 mg IL-2 2MU,QW, 3 W	Lung cancer Lung cancer	Efficacy, AEs Efficacy, AEs, QOL
ianping Jiang, et al 2009	26	26	30	22	43–76	48–73	Elemene 300 mg, QW	bleomycin 30 mg	Lung cancer, breast cancer and other cancers	Efficacy, AEs
angfang Si, et al 2015	20	20	22	18	45–72	51-78	DDP, 30 mg + elemene 200 mg/m <sup>2</sup> , QW, 3 W	DDP 30 mg, QW, 3 W	Lung cancer, breast cancer and other cancers	Efficacy, AEs, QOL
Siming Chen, et al 2012	23	23/23	41	28	61.2±5.2	$61.2 \pm 5.2$	IL-2 2MU + elemene 300 mg, QW	IL- 2 2MU, DDP 60 mg	Lung cancer	Efficacy, AEs, QOL
Zhijie Li, et al 2006 /an Gao, et al 2010	38 35	40 35	48 35	30 35	42–77 18–75	42–77 18–75	Elemene 600~800 mg DDP 40 mg/m <sup>2</sup> , elemene	DDP 60~80 mg DDP, 40 mg/m <sup>2</sup>	Lung cancer Lung cancer, breast cancer	Efficacy, AEs Efficacy, AEs
idan Wang, et al 2012	50	50	57	43	$54.3 \pm 3.4$	$54.7 \pm 3.6$	600 mg DDP 20 mg/m <sup>2</sup> , elemene	DDP40 mg/m <sup>2</sup> ,QW, 2W	and other cancers Lung cancer	Efficacy, AEs
/iming Kong, et al 2012	30	30	NA	NA	50-72	46-71	400 mg/m <sup>2</sup> , QW, 2W Elemene, 500 mg in 100	DDP60 mg,qw	Lung cancer	Efficacy, AEs
Hongsong Wu, et al 2011	30	30	30	30	45-69	43-70	ml saline, QW, 3W elemene 300 mg/m <sup>2</sup>	DDP 50 ma/m <sup>2</sup>	Lung cancer, breast cancer	Efficacy, AEs
lichun Zhong, et al 2011	46	50	34	62	38-72	38-72	Elemene 500 mg in 100 ml	DDP 80 mg	and other cancers Lung cancer, breast cancer	Efficacy, AEs
Jianbin Zhang, et al 2013	45	45	52	58	62.74±6.8	$61.5 \pm 6.7$	saline Elemene 400 mg in 80 ml	Bleomycin 60 mg	and other cancers Lung cancer	Efficacy, AEs,
							saline		•	QOL
Aifen Wang, et al 2011	18	18	19	17	66	65	elemene 300 mg	Bleomycin, 30 mg	Lung cancer, breast cancer and other cancers	Efficacy, AEs, QOL
3oquan Yang, et al 2000	30	30	38	22	28–75	29–74	Elemene 200–300 mg	DDP 60-80 mg	Lung cancer, breast cancer and other cancers	Efficacy, AEs, QOL
Jin Qi, et al 2011	24	26	NA	NA	NA	NA	Elemene 200 m g/m <sup>2</sup>	DDP 50 mg/m <sup>2</sup>	Lung cancer, breast cancer and other cancers	Efficacy, AEs
linsheng Yu, et al 2015	81	61	78	64	50-72	50-72	Elemene 300 mg/m <sup>2</sup> , QW, 4 W + thermal therapy, TIW	Elemene 300 mg/m <sup>2</sup> , QW, 4 W	Lung cancer, breast cancer and other cancers	Efficacy, AEs
Chang Liu, et al 2011	69	69	65	73	38–75	39–77	DDP 30 mg + elemene	DDP 60 mg, QW, 4 W	Lung cancer, breast cancer	Efficacy, AEs,
anying Sun, et al 2012.	32	32	44	20	43–75	43–75	300 mg, QW, 4 W Elemene 300 mg/m <sup>2</sup> , QW,	DDP 40-60 mg, QW, 2	and other cancers Lung cancer	QOL Efficacy, AEs,
iujie Gao, et al 2013	34	34	43	25	65.1±12.2	64.2±12.4	2 W Elemene 200 mg/m <sup>2</sup> +	W Elemene 200 mg/m <sup>2</sup>	Lung cancer, breast cancer	QOL Efficacy, AEs
Chang Liu, et al 2011	38	37	49	26	70.3±2.4	69.5+2.6	thermal therapy Elemene 300 mg +DDP	Elemene 300 mg +	and other cancers Lung cancer, breast cancer	Efficacy, AEs
ing Zhou, et al 2012	27	25	27	25	26-82	26-82	30 mg, thermal therapy elemene 400 mg	DDP30 mg Staphylococcal	and other cancers Lung cancer, breast cancer	Efficacy, AEs
'onghua Hu, et al 2016	50	50	NA	NA	40-75	40-75	DDP + elemene	enterotoxin 40 mL DDP	and other cancers Lung cancer, breast cancer	Efficacy, AEs
Kiaoying Yao, et al 2002	30	30	52	8	18–75	18–75	elemene 400 mg, QW, 3 W	DDP 60 mg, QW, 3 W	and other cancers Lung cancer, breast cancer	Efficacy, AEs
Jianqing Chen, et al 2004	32	32	40	24	26–70	26–71	Elemene 200 mg/m <sup>2</sup> +DDP 50 mg/m <sup>2</sup> , QW,	DDP 50 mg/m <sup>2</sup> , QW, 3 W	and other cancers Lung cancer, breast cancer and other cancers	Efficacy, AEs
Jianming Lu, et al 2011	30	30	35	25	34–74	41–76	3 W Elemene 500 mg	DDP 50 mg/m <sup>2</sup>	Lung cancer, breast cancer	Efficacy, AEs
Ping Huang, et al 2000	30	30	36	24	32-70	32-70	Elemene 500 mg +	DDP 60 mg	and other cancers Lung cancer, breast cancer	Efficacy, AEs,
Ping Wang, et al 2002	30	20	34	16	58.25±20.12	59.16±19.67	DDP60 mg Elemene 500 mg	DDP 80 mg	and other cancers Lung cancer, breast cancer	QOL Efficacy, AEs

(continued)

#### Table 1 (continued).

		Ν	S	ex		Age	Interve	entions		
Studies	Т	C	М	F	Т	C	Т	C	Cancers	Outcomes
Guoqiang Shi, et al 2007	25	25	30	20	$58\pm10$	$59\pm12$	Elemene 300 mg	DDP50 mg	Lung cancer, breast cancer and other cancers	Efficacy, AEs, QOL
Ming Li, et al 2008	26	26	30	22	45–69	43–70	Elemene 300 mg	DDP60 mg	Lung cancer, breast cancer and other cancers	Efficacy, AEs
Yanjun Wang, et al 2009	43	32	45	30	34–78	38–78	Elemene 400 mg	hyperosmotic glucose 40 ml	Lung cancer	Efficacy, AEs
Aihe Ye, et al 2001	46	50	64	32	40-70	42-68	Elemene 400~ 600 mg	DDP 60 $\sim$ 80 mg	Lung cancer	Efficacy, AEs
Lixin Gu, et al 2003	20	20	25	15	32–71	34–70	Elemene 400 mg, QW, 2 W	DDP 40 mg/m <sup>2</sup> , QW, 2 W	Lung cancer, breast cancer and other cancers	Efficacy, AEs
Shuntong Lin, et al 1996	11	10	11	10	37-70	37-70	Elemene 100–300 mg	DDP 40 mg	Lung cancer	Efficacy, AEs
Youjuan Jiang, et al 1997	17	17	28	6	40-72	44–71	Elemene 200-300 mg	DDP 40 mg	Lung cancer, breast cancer and other cancers	Efficacy, AEs
Haibin Li, et al 2007	30	29	36	23	48–69	48–69	Elemene 200 mg	DDP 100 mg/m <sup>2</sup>	Lung cancer, breast cancer and other cancers	Efficacy
Xianli Bai, et al 2005	24	23	30	17	$56 \pm 12$	$60 \pm 13$	Elemene 200 mg/m <sup>2</sup> , QW, 2 W	DDP 40 mg/m <sup>2</sup> , QW, 2 W	Lung cancer, breast cancer and other cancers	Efficacy, AEs

AEs = adverse events; C = control group; DDP = cisplatin; F = female; KPS = Karnofsky Performance Status Scale; M = male; MU = million units; NA = not available; QOL = quality of life; QW = once per week; T = treatment group; TIW = three times a week; W = week.

high. Blinding was not detailed in these studies. The risks of selective reporting were regarded to be low in these studies. The detailed information of quality assessment is presented in Table 2.

#### 3.3. Results of meta-analysis

#### 3.3.1. Efficacy of controlling malignant pleural effusion.

3.3.1.1. CR. Forty-six clinical studies reported outcomes of complete resolution of the pleural effusion. As there was no

### Table 2

Methodological quality evaluation of included studies.

Studies	Random	Allocation	Blinding	Selective reporting	Other bias
Fang Zhao,et al 2015	Y	N	N	N	NR
Jingbo Sun, et al 2014	Y	Ν	Ν	N	NR
Jianpeng Li, et al 2014	Y	N	Ν	Ν	NR
Jinna Wang, et al 2015	Y	N	Ν	Ν	NR
Bianrong Wu, et al 2015	Y	N	Ν	N	NR
Yihe Zhang, et al 2016	Ŷ	N	N	N	NR
Jing Su, et al 2014	Ŷ	N	N	N	NR
Ke Dong, et al 2015	Ý	N	Ň	N	NR
Zhuangwei Li, et al 2016	Ŷ	N	Ň	N	NR
Zan Liu, et al 2016	Ŷ	Ň	Ň	N	NR
Hong Wang, et al 2007	Ý	Ň	N	N	NR
Zhihong Feng, et al 2007	Ý	N	N	N	NR
Lianping Jiang, et al 2009	N	N	N	N	NR
Fangfang Si, et al 2005	Y	N	N	N	NR
Siming Chen, et al 2012	f Y	N	N	N	NR
	Y Y		N		NR
Zhijie Li, et al 2006		N		N	
Yan Gao, et al 2010	Y	N	N	N	NR
Lidan Wang, et al 2012	Y	N	N	N	NR
Yiming Kong, et al. 2012	Y	N	N	N	NR
Hongsong Wu, et al 2011	Y	N	N	N	NR
Jichun Zhong, et al 2011	Y	N	N	N	NR
Jianbin Zhang, et al 2013	Y	N	N	N	NR
Aifen Wang, et al 2011	NA	N	N	N	NR
Boquan Yang, et al 2000	NA	Ν	N	N	NR
Jin Qi, et al 2011	NA	N	N	N	NR
Jinsheng Yu, et al 2015	Y	N	N	N	NR
Chang Liu, et al 2011	Y	N	N	N	NR
Lanying Sun, et al 2012	Y	N	N	N	NR
Liujie Gao, et al 2013	Y	N	Ν	Ν	NR
Chang Liu, et al 2011	Y	N	N	N	NR
Ling Zhou, et al 2012	Y	N	Ν	Ν	NR
Yonghua Hu, et al 2016	Y	N	Ν	N	NR
Xiaoying Yao, et al 2002	Y	Ν	Ν	N	NR
Jianging Chen, et al 2004	NA	N	N	N	NR
Jianming Lu, et al 2011	Y	N	Ň	N	NR
Ping Huang, et al 2000	Ŷ	N	Ň	N	NR
Ping Wang, et al 2002	Ý	Ň	N	N	NR
Guogiang Shi, et al 2007	Ŷ	Ň	Ň	N	NR
Ming Li, et al 2008	Ý	N	N	N	NR
Yanjun Wang, et al 2009	Ý	N	N	N	NR
Aihe Ye, et al 2001	Y	N	N	N	NR
Lixin Gu, et al 2003	f Y	N	N	N	NR
	Y Y				NR
Shuntong Lin, et al 1996		N	N	N	
Youjuan Jiang, et al 1997	Y	N	N	N	NR
Haibin Li, et al 2007	Y	N	N	N	NR
Xianli Bai, et al 2005	Y	N	N	N	NR

N=no; NA=not available; NR=not reported; Y=yes.

Table 2 Risk of bias: review authors' judgements about each risk of bias item for each included study.

Jina Wang (2015) Bianrong Wu (2015) Ke Dong (2015) Zhije Li (2006) Lidan Wang (2012) Jianbin Zhang (2012) Jianbin Zhang (2013) Liujie Gao (2013) Guoqiang Shi (2007) Yaniya (2009) Aihe Ye (2001) Shuntong Lin (1996) Subtotal (I-squared = 0.0%, p = 0.948) Other cancer Jingbo Sun (2014) Jianpeng Li (2014) Jianpeng Li (2014) Jianpeng Li (2016) Zan Liu (2016) Zan Liu (2016) Lidanying Si (2007) Yan Gao (2011) Jichun Zhong (2001) Jichun Zhong (2001) Jichun Zhong (2001) Jichun Zhong (2001) Jichun Zhong (2011) Jichun Zhong (2012) Jing Sun (2011) Jichun Zhong (2012) Jing Sun (2011) Jichun Zhong (2000) Fangfang Si (2011) Jichun Zhong (2011) Jichun Zhong (2012) Jing Sun (2012) Jing Sun (2011) Jing Sun (2012) Chang Liu (2011) Jing Yao (2002) Jing Yao (2002) Jianpeng Yu (2015) Chang Liu (2011) Jing Yao (2002) Jing Yao (2002) Jing Huang (2000) Ming Li (2008) Lixin Gu (2003) Zan Liu (2016) Jing Yao (2002) Ming Li (2008) Lixin Gu (2003) Zan Cia (2003) Jing Yao (2002) Ming Li (2008) Lixin Gu (2003) Zan Cia (2003) Jing Yao (2002) Ming Li (2008) Lixin Gu (2003) Zan Cia (2003) Jing Yao (2002) Ming Li (2008) Lixin Gu (2003) Zan Cia (2003) Jianpeng Li (2008) Lixin Gu (2003) Zan Cia (2003) Jianpeng Li (2008) Lixin Gu (2003) Zan Cia (2003) Jianpeng Li (2008) Lixin Gu (2003) Zan Cia (2003) Zan Cia (2003) Zan Cia (2004) Jianpeng Li (2008) Lixin Gu (2003) Zan Cia (2003) Zan Cia (2003) Zan Cia (2003) Zan Cia (2004) Jianpeng Li (2008) Lixin Gu (2003) Zan Cia (2003) Zan Cia (2003) Zan Cia (2004) Jianpeng Li (2008) Lixin Gu (2003) Zan Cia (2004) Jianpeng Li (2008) Lixin Gu (2003) Zan Cia (2004) Jianpeng Li (2008) Lixin Gu (2003) Zan Cia (2003) Zan Cia (2004) Jianpeng Li (2008) Lixin Gu (2003) Zan Cia (2004) Jianpeng Lia (2004) Jianpeng Li (2	(95% CI)	% Weight
Jingbo Sun (2014) Jianpeng Li (2014) Yihe Zhang (2016) Zhuangwei Li (2016) Zan Liu (2016) Lianping Jiang (2009) Fangfang Si (2015) Yan Gao (2010) Haisong Wu (2011) Jichun Zhong (2011) Aifen Wang (2011) Jinsheng Yu (2015) Chang Liu (2011) Jing Yao (2002) Jianqing Chen (2004) Jianqing Chen (2004) Jianqing Liu (2011) Ping Huang (2000) Ping Wang (2002) Ming Li (2008) Lixin Gu (2003) Youjuan Jiang (1997)	0 (0.23, 4.37) 0 (0.72, 3.78) 1 (0.63, 3.65) 1 (0.71, 3.30) 1 (0.76, 3.52) 0 (0.64, 2.42) 1 (0.75, 4.50) 1 (0.75, 4.50) 2 (0.60, 4.36) 5 (0.41, 1.39) 3 (0.82, 3.03) 1 (0.50, 6.55) 3 (0.52, 6.42) 7 (0.91, 3.09) 5 (0.32, 4.24) 7 (1.20, 1.80)	0.67 1.67 1.48 1.91 1.92 2.37 1.40 3.82 1.18 4.06 2.45 0.71 0.80 2.82 0.72 27.98
Xianli Bai (2005) 1.05 (0 Subtotal (I-squared = 0.0%, p = 0.928) 1.33 (1	$\begin{array}{c} (1.01, 2.55) \\ (0.72, 4.16) \\ (0.62, 2.76) \\ (0.64, 1.59) \\ (0.64, 1.59) \\ (0.42, 1.39) \\ (0.72, 1.68) \\ (0.73, 1.61) \\ (0.73, 1.61) \\ (0.57, 2.22) \\ (0.73, 0.61) \\ (0.22, 3.66) \\ (0.85, 47.72) \\ (0.72, 5.59) \end{array}$	0.76 3.23 2.49 0.71 0.69 1.43 1.15 1.35 0.71 1.20 0.67 3.22 1.39 9.58 4.92 1.45 2.12 4.68 4.29 5.12 5.80 2.53 1.27 0.80 0.25 1.00 1.26 2.35 2.08 72.02 100.00

significant heterogeneity among the pooled studies, the fixed effect model was used. The results showed that the complete control of the pleural effusion in the experimental group was higher than that of the control group, and the difference was statistically significant [RR=1.37, 95% CI: 1.23–1.52; P < .05]. Sub-group analysis was also performed based on different types of treatment and diseases. With regards to different types of cancer, the results showed that

the rate of CR was significantly higher than that of the control group in lung cancer patients [RR=1.47, 95% CI:1.20–1.80; P < .05]. The RR was 1.47 in lung cancer patients and it was 1.33 in various cancers (Fig. 2). For different types of treatments, elemene was proved to be superior to other medications including DDP, BLM, and IL-2, and the differences were statistically significant (Supplemental Figure 1, http://links.lww.com/MD/C555).

3.3.1.2. Overall response. There were 46 clinical trials presented the data of overall response. As there was no significant heterogeneity ( $I^2\% < 50\%$ ), the fixed effect model was used in this meta-analysis. The pooled results showed that the ORR of the experimental group was higher than that of the control group, and the difference was statistically significant [RR=1.16, 95%]

CI: 1.08–1.23; P < .05]. This result indicated that patients received elemene could have a better overall response. The subgroup analysis showed that the lung cancer patients treated with elemene had a 1.20 times chance of controlling malignant pleural effusion, while it was 1.14 times for all other included cancer patients (Fig. 3). As for different treatments, the elemene

	RR (95% CI)	% Weight
ing cancer ang Zhao (2015) ina Wang (2015) ianrong Wu (2015) ie Dong (2015) hihong Feng (2015) iming Chen (2012) hijie Li (2006) idan Wang (2012) ianbin Zhang (2012) ianbin Zhang (2013) iujie Gao (2013) iujie Gao (2013) iuoqiang Shi (2007) anjun Wang (2009) ihe Ye (2001) huntong Lin (1996) ubtotal (I-squared = 0.0%, p = 0.854)	$\begin{array}{c} 0.95 & (0.53, 1.73) \\ 1.27 & (0.84, 1.94) \\ 1.24 & (0.77, 2.02) \\ 1.29 & (0.84, 1.99) \\ 1.45 & (0.93, 2.26) \\ 1.16 & (0.71, 1.89) \\ 1.47 & (0.93, 2.34) \\ 1.03 & (0.78, 1.37) \\ 1.39 & (0.84, 2.30) \\ 0.78 & (0.52, 1.17) \\ 1.18 & (0.79, 1.77) \\ 1.25 & (0.75, 2.06) \\ 1.45 & (0.82, 2.54) \\ 1.30 & (0.89, 1.88) \\ 1.09 & (0.52, 2.31) \\ 1.20 & (1.07, 1.34) \end{array}$	1.28 2.39 1.79 2.19 2.14 1.70 1.98 4.79 1.67 3.32 2.46 1.63 1.49 2.95 0.76 32.53
Other cancer ingbo Sun (2014) ianpeng Li (2014) ihe Zhang (2016) ing Su (2014) huangwei Li (2016) an Liu (2016) long Wang (2007) ianping Jiang (2009) angfang Si (2015) an Gao (2010) laisong Wu (2011) ichun Zhong (2011) ichun Zhong (2011) ingen Wang (2000) in Qi (2011) insheng Yu (2015) chang Liu (2011) anying Sun (2012) chang Liu (2011) ing Zhou (2012) onghua Hu (2016) iaoying Yao (2002) ianqing Chen (2004) ianming Lu (2011) ing Huang (2000) ing Wang (2002) iang Huang (2003) oujuan Jiang (1997) ianli Bai (2005) ubtotal (l-squared = 0.0%, p = 0.998)	→ 1.86 (0.79, 4.38) 1.08 (0.76, 1.53) 1.27 (0.80, 2.00) 1.04 (0.63, 1.73) 1.33 (0.78, 2.27) 1.25 (0.75, 2.08) 0.85 (0.53, 1.38) 1.03 (0.64, 1.66) 1.43 (0.74, 2.75) 1.48 (0.89, 2.46) 1.40 (0.78, 2.52) 1.30 (0.89, 1.88) 0.96 (0.54, 1.70) 1.17 (0.77, 1.79) 1.23 (0.75, 2.01) 1.15 (0.83, 1.58) 1.06 (0.81, 1.38) 1.06 (0.81, 1.38) 1.27 (0.80, 2.02) 1.21 (0.81, 1.32) 1.21 (0.81, 1.32) 1.01 (0.66, 1.53) 0.83 (0.59, 1.18) 1.09 (0.73, 1.62) 1.08 (0.74, 1.56) 1.03 (0.66, 1.60) 1.26 (0.80, 1.99) 0.99 (0.63, 1.56) 1.20 (0.73, 1.97) 1.33 (0.75, 2.39) 1.03 (0.62, 1.72) 1.33 (0.84, 2.10) 1.05 (0.61, 1.80) 1.14 (1.05, 1.23)	0.59 3.32 1.99 1.67 1.52 1.62 2.33 1.93 1.00 1.68 1.31 2.95 1.38 2.24 1.66 4.28 5.65 2.30 4.12 2.50 2.30 4.12 2.50 2.30 4.12 2.50 2.30 4.12 2.50 2.30 4.12 2.50 2.30 1.96 2.50 2.04 1.71 1.52 1.53 1.92 1.56 67.47

Study ID	RR (95% CI)	% Weight
lung cancer		
Bianrong Wu (2015)	- 1.80 (0.84, 3.84)	3.08
Ke Dong (2015)	- 1.89 (0.97, 3.68)	3.89
Zhihong Feng (2015)	1.63 (0.99, 2.69)	6.51
Siming Chen (2012)	1.24 (0.69, 2.22)	4.90
Zhijie Li (2006)	1.33 (0.88, 2.02)	9.05
Yiming Kong (2012)	1.36 (0.78, 2.38)	5.40
Liujie Gao (2013)	1.31 (0.75, 2.28)	5.72
Guoqiang Shi (2007)	1.47 (0.78, 2.75)	4.22
Subtotal (I-squared = 0.0%, p = 0.973)	1.46 (1.20, 1.78)	42.77
Other cancer Jianpeng Li (2014) Zhuangwei Li (2016) Hong Wang (2007) Fangfang Si (2015)	1.53 (0.87, 2.70) 1.39 (0.71, 2.71) 0.75 (0.33, 1.70) 2.25 (0.83, 6.12)	4.09 4.17
Haisong Wu (2011)	1.45 (0.78, 2.68)	
Boquan Yang (2000)	1.33 (0.80, 2.22)	
Chang Liu (2011)	1.17 (0.77, 1.77)	
Yonghua Hu (2016)	0.82 (0.57, 1.18)	
Ping Huang (2000)	1.56 (0.89, 2.73)	
Lixin Gu (2003)	······································	
Subtotal (I-squared = 27.9%, p = 0.187)	1.26 (1.05, 1.50)	
Overall (I-squared = 0.0%, p = 0.536)	1.35 (1.18, 1.54)	100.00
.0991 1	10.1	

had a 1.16 times chance in achieving overall response than other interventions (Supplemental Figure 2, http://links.lww.com/MD/C555).

3.3.1.3. Improvement in QOL. 18 clinical trials reported data of improvement in QOL. Because of the homogeneity of included studies (P=.536,  $I^2$ %=0%), the fixed effect model was used. As shown in Figure 4, the meta-analysis results showed that patients in the experimental group had a better chance in improving QOL than those in the control group [RR=1.35, 95% CI:1.18–1.54; P<.05]. Subgroup-analysis suggested that patients with lung cancer seemed to benefit most from the treatment of elemene [RR=1.46, 95% CI:1.20–1.78; P<.05].

#### 3.4. Adverse events

**3.4.1.** Chest pain. Thirty-three clinical studies reported the incidence of chest pain due to the treatment. As it was heterogeneous (P = .019,  $I^2 \% = 51.9\%$ ), so the random effect model was used for meta-analysis. Overall results showed that the incidence of chest pain in the experimental group was significantly higher than that in the control group [RR=1.39,

95% CI (1.18–1.64)]. Subgroup analysis based on the type of disease was performed. As shown in Figure 5, the results showed no significant difference in the incidences of chest pain between the experimental group and control group in lung cancer studies [RR=1.10, 95% CI (0.89–1.34)]. In the 21 studies of various malignancies, the incidence of chest pain in the treatment group was significantly higher than that in the control group [RR= 1.95, 95% CI (1.47–2.57)].

**3.4.2.** Fever. 30 clinical controlled studies reported the incidence of fever, and the fixed effect model was used as there was no significant heterogeneity across the studies. The overall results showed that the incidence of fever in the treatment group was higher than that in the control group, with a statistically significant difference [odds ratio (OR)=1.43, 95% CI (1.17–1.74)]. As shown in Figure 6, subgroup analysis based on the type of disease showed that the incidence of fever in the treatment group was not significantly higher than that in the control group (OR=1.19, 95% CI (0.93–1.53)] in lung cancer patients, but not for various malignancies [OR=1.80, 95% CI (1.31–2.46)].

Study ID		% Neight
lung cancer		
Bianrong Wu (2015)	1.98 (0.79, 4.99)	2.91
Ke Dong (2015)	1.04 (0.71, 1.52)	14.56
hihong Feng (2015)		4.01
Siming Chen (2012)	0.34 (0.08, 1.50)	3.26
(hijie Li (2006)	0.99 (0.70, 1.42)	16.93
(iming Kong (2012)	0.27 (0.03, 2.32)	1.95
ianbin Zhang (2013)	0.53 (0.14, 2.01)	2.98
iujie Gao (2013)	1.05 (0.57, 1.93)	7.24
Suoqiang Shi (2007)		3.26
Yanjun Wang (2009)	0.28 (0.10, 0.79)	7.25
Aihe Ye (2001)	31.21 (1.93, 503.89)	
Shuntong Lin (1996)	10.50 (0.68, 163.13)	0.34
idan Wang (2012)		0.00
Subtotal (I-squared = 51.9%, p = 0.019)		64.99
Other cancer	1 64 10 54 5 04	10
lianpeng Li (2014)		2.12
(ihe Zhang (2016)		1.83
ling Su (2014)		0.54
an Liu (2016)		2.01
long Wang (2007)		1.90
ianping Jiang (2009)		0.56
angfang Si (2015)		1.60
(an Gao (2010)		2.02
lichun Zhong (2011)	27.89 (1.72, 452.70)	
Aifen Wang (2011)		0.54
Boquan Yang (2000)		0.26
lin Qi (2011)		0.52
anying Sun (2012)		3.63
Chang Liu (2011)		6.59
ing Zhou (2012)		1.17
Yonghua Hu (2016)		1.03
lianging Chen (2004)	8.03 (0.45, 143.54) (	0.27
lianming Lu (2011)	2.00 (0.78, 5.13)	2.79
Ping Huang (2000)	13.51 (0.81, 225.10)	0.29
ixin Gu (2003)		2.40
(ianli Bai (2005)		2.65
Chang Liu (2011)	(Excluded)	0.00
Subtotal (I-squared = 19.4%, p = 0.209)		35.01
Overall (I-squared = 42.7%, p = 0.006)	1.39 (1.18, 1.64)	100.00
i	1	
.00198 1	504	

**3.4.3.** *Myelosuppression.* Seventeen clinical controlled studies provided the rates of myelosuppression. Due to homogeneity across the studies, the fixed effect model was used. The overall results showed that the incidence of myelosuppression in the treatment group was significantly lower, when compared with the control group [OR=0.40, 95% CI (0.33–0.49)]. As illustrated in Figure 7, the subgroup analysis was done based on different cancers. There was significant difference in the incidence of myelosuppression [OR=0.47, 95% CI (0.35–0.64)] in patients with lung cancer.

**3.4.4. Gastrointestinal adverse reactions.** Thirty-five clinical studies reported the incidence of gastrointestinal reactions. The fixed effect model was used for this meta-analysis. As shown in

Figure 8, the overall results showed that the incidence of gastrointestinal reactions in the treatment group was statistically significantly lower when compared with that of the control group [OR=0.50, 95% CI (0.41–0.60)]. Results from the sub-group analysis showed that there was significant difference in the incidence of gastrointestinal reactions between the 2 groups in lung cancer patients [OR=0.56, 95% CI (0.43–0.75)].

**3.4.5.** Publication bias assessment. The data of efficacy was used to detect the publication bias. Begg test was used to calculate the significance of publication bias. As illustrated by the funnel plot, the figure is basically symmetrical, suggesting no significant risk of bias (P > .05) and indicating that the meta-analysis results

Study D	RR (95% CI)	% Weight
ung cancer		
Bianrong Wu (2015)	1.76 (0.35, 8.90)	1.54
(e Dong (2015)	1.10 (0.71, 1.71)	16.44 4.24
hihong Feng (2015)	0.70 (0.21, 2.30) 1.28 (0.32, 5.19)	2.21
iming Chen (2012)	1.13 (0.74, 1.73)	17.61
idan Wang (2012)	1.00 (0.15, 6.83)	1.45
iming Kong (2012)	0.53 (0.10, 2.70)	2.80
anbin Zhang (2013)	- 1.00 (0.06, 15.51)	
iujie Gao (2013)	1.12 (0.45, 2.80)	5.12
anjun Wang (2009)	0.59 (0.25, 1.41)	7.86
ihe Ye (2001)	• 18.79 (1.13, 312.6	
huntong Lin (1996)	9.95 (0.64, 155.47	
ubtotal (I-squared = 0.0%, p = 0.471)	1.19 (0.93, 1.53)	60.84
	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
ther cancer		
anpeng Li (2014)	1.47 (0.26, 8.33)	1.46
ihe Zhang (2016)	4.57 (0.23, 91.66)	
ng Su (2014)	0.96 (0.21, 4.32)	2.21
an Liu (2016)	1.45 (0.26, 8.02)	1.47
ong Wang (2007)	1.24 (0.43, 3.53)	3.88
ianping Jiang (2009)	0.54 (0.11, 2.70)	2.79
angfang Si (2015)	1.83 (0.37, 9.04)	1.51
an Gao (2010)	1.46 (0.26, 8.25)	1.46
chun Zhong (2011)	22.95 (1.40, 376.6	
ifen Wang (2011)	0.37 (0.04, 3.25)	2.06
oquan Yang (2000)	4.70 (0.23, 94.01) 1.08 (0.16, 7.10)	0.37
n Qi (2011)	1.96 (1.13, 3.40)	11.21
anying Sun (2012)	2.33 (0.67, 8.12)	2.31
hang Liu (2011)	1.86 (0.36, 9.58)	1.50
ng Zhou (2012)	0.50 (0.10, 2.52)	2.89
anming Lu (2011)	1.88 (0.37, 9.58)	1.49
ing Huang (2000)	9.47 (0.55, 164.57	
ubtotal (I-squared = 0.0%, p = 0.688)	1.80 (1.31, 2.46)	39.16
, , , , , , , , , , , , , , , , , , ,		
overall (I-squared = 0.0%, p = 0.481)	1.43 (1.17, 1.74)	100.00
.00266 1	377	

are stable and reliable (Supplemental Figure 3, http://links.lww. com/MD/C555).

#### 4. Discussion

Elemene has been widely used in the treatment of cancer, including complications of cancer.<sup>[59]</sup> In recent years, several publications supporting elemene in the treatment of malignant pleural effusion have been reported, but their findings are established based on limited number of patients.<sup>[8,12]</sup> In this metaanalysis, we found that elemene could significantly improve the short-term control of malignant pleural effusion. Subgroup results showed that the effective rate of elemene in the treatment of malignant pleural effusion was significantly higher than that of the DDP group. Meanwhile, elemene did not significantly increase the incidence of adverse events. Meta-analysis results of this study showed that, elemene alone or combined with DDP or BLM could improve the CR rate [OR = 1.55, 95% CI (1.34, 1.79)] when compared with DDP, BLM. Subgroup analysis showed that elemene combined with DDP or BLM or hyperthermia could improve complete control of the pleural effusion in lung cancer patients [OR = 1.67, 95% CI (1.28, 2.17)]. In term of QOL improvement, elemene alone or combined with DDP or BLM could improve QOL [OR = 1.58, 95% CI (1.29, 1.93)]. Subgroup analysis showed that this beneficial effectiveness existed in both lung cancer and other malignant tumors.

A few meta-analyses<sup>[8,12]</sup> have been published to evaluate the efficacy and safety of elemene in treating various types of tumors, including lung cancer. Xu et al<sup>[60]</sup> performed a study to assess the efficacy of elemene in cancer treatment. A total of 11 trials were included after their search of several databases. The results

Study ID	RR (95% CI)	% Weight
lung cancer         Bianrong Wu (2015)         Ke Dong (2015)         Zhihong Feng (2015)         Zhijie Li (2006)         Lidan Wang (2012)         Yiming Kong (2012)         Jianbin Zhang (2013)         Guoqiang Shi (2007)         Aihe Ye (2001)         Shuntong Lin (1996)         Siming Chen (2012)         Liujie Gao (2013)         Subtotal (I-squared = 27.0%, p = 0.196) ♦	0.16 (0.02, 1.24) 0.65 (0.40, 1.04) 0.15 (0.01, 2.88) 0.73 (0.48, 1.12) 0.15 (0.01, 2.86) 0.06 (0.00, 0.90) 0.52 (0.10, 2.71) 0.11 (0.01, 1.87) 0.11 (0.01, 1.91) 0.22 (0.01, 4.07) (Excluded) (Excluded) 0.47 (0.35, 0.64)	11.10 1.32 12.23 1.33 4.11 1.54 1.97 1.97 0.94 0.00 0.00
Other cancer Jianpeng Li (2014) Yihe Zhang (2016) Jing Su (2014) Zan Liu (2016) Hong Wang (2007) Fangfang Si (2015) Yan Gao (2010) Jichun Zhong (2011) Jin Qi (2011) Chang Liu (2011) Lanying Sun (2012) Chang Liu (2011) Jianming Lu (2011) Jianming Lu (2011) Ping Huang (2000) Ping Wang (2002) Lixin Gu (2003) Xianli Bai (2005) Aifen Wang (2011) Boquan Yang (2000) Subtotal (I-squared = 52.8%, p = 0.006) Overall (I-squared = 44.1%, p = 0.008)	0.08 (0.00, 1.33) 0.15 (0.02, 1.12) 0.08 (0.00, 1.25) 0.35 (0.01, 8.12) 0.19 (0.01, 3.64) 2.86 (0.12, 66.44) 0.20 (0.05, 0.83) 0.05 (0.00, 0.88) 0.23 (0.01, 4.61) 0.74 (0.53, 1.02) 0.08 (0.00, 1.36) 0.52 (0.14, 1.96) 0.19 (0.02, 1.52) 0.04 (0.00, 0.62) 0.06 (0.00, 1.01) 0.16 (0.01, 2.98) 0.11 (0.01, 1.81) (Excluded) (Excluded) 0.35 (0.26, 0.47) 0.40 (0.33, 0.49)	2.88 2.91 0.58 1.16 4.0.20 4.44 4.19 0.91 21.13 2.66 2.30 2.18 6.30 3.09 1.28 2.00 0.00 0.00 60.92
00245 1 Figure 7. Forest plot of comparison: elemene versus other med	408	

showed that elemene combined with chemotherapy had a significant rise in the number of patients who achieved treatment response, associated with low risk of adverse events. However, their findings failed to prove elemene was better in improving survival rate. Another study by Chen et al<sup>[8]</sup> evaluated the clinical efficacy of elemene in treating lung cancer patients with malignant pleural effusion. They included a total of 14 RCTs with 1298 cancer patients for the meta-analysis and the results showed that the objective response rate of the elemene was significantly higher than that of the control group, especially when compared with DDP. Recently, Wang et al<sup>[12]</sup> performed another meta-analysis to assess the clinical efficacy of elemene versus DDP in treating malignant pleural effusion caused by lung cancer. They included 14 studies with a total of 732 lung cancer patients. Their findings suggested that the ORR in elemene group was significantly higher than that of the DDP group. These results are in accordance with our findings. Our results showed that elemene was not only exhibiting the ability of controlling malignant pleural effusion, but also improving QOL with tolerable adverse events. With regard to adverse reactions, we also found that the incidences of chest pain and fever in elemene group were increased when compared with control group, but the rates of myelo-suppression and gastrointestinal reaction were similar or even decreased when compared with other medications. These may be caused by the varied types of cancer, different combination of treatment and other aspects. The subgroup analyses showed that elemene was most effective in treating pleural effusion caused by lung cancer.

Though the results of our meta-analysis show beneficial clinical outcomes and safety when using elemene for cancer patients with malignant pleural effusion, several limitations exist in our study. First, the overall qualities of the included studies are moderate,

Study ID	RR (95% CI)	% Weight
lung cancer		
Bianrong Wu (2015)	0.73 (0.18, 2.99)	
Ke Dong (2015)	0.94 (0.48, 1.85)	
hihong Feng (2015)	0.75 (0.26, 2.18)	2.43
iming Chen (2012)	0.28 (0.03, 2.35)	
hijie Li (2006)	0.76 (0.43, 1.33)	
idan Wang (2012)	0.53 (0.14, 2.01)	
iming Kong (2012)	0.11 (0.01, 0.77)	3.87
ianbin Zhang (2013)	0.51 (0.05, 5.44)	0.70
iujie Gao (2013)	1.00 (0.31, 3.18)	1.78
Suoqiang Shi (2007)	0.51 (0.20, 1.30)	3.82
anjun Wang (2009)	0.99 (0.38, 2.62)	2.44
sihe Ye (2001)	0.04 (0.00, 0.59)	
Shuntong Lin (1996)	0.53 (0.21, 1.37)	3.05
Subtotal (I-squared = 6.4%, p = 0.382)	0.56 (0.43, 0.75)	
Other cancer		0.00
ianpeng Li (2014)	0.15 (0.02, 1.12)	
(ihe Zhang (2016)	0.42 (0.09, 2.04)	
ing Su (2014)	0.11 (0.02, 0.76)	
an Liu (2016)	1.93 (0.19, 20.05	)0.36
long Wang (2007)	1.08 (0.40, 2.95)	
ianping Jiang (2009)	0.21 (0.01, 4.28)	0.86
angfang Si (2015)	0.70 (0.13, 3.78)	
/an Gao (2010)	0.92 (0.53, 1.61)	
ichun Zhong (2011)	0.03 (0.00, 0.51)	
ifen Wang (2011)	0.17 (0.01, 3.00)	1.15
loquan Yang (2000)	0.21 (0.01, 4.26)	
in Qi (2011)	0.14 (0.02, 1.05)	2.91
anying Sun (2012)	0.05 (0.00, 0.76)	4.49
Chang Liu (2011)	0.83 (0.27, 2.53)	2.13
ing Žhou (2012)	0.93 (0.06, 14.09	
ianging Chen (2004)	1.27 (0.48, 3.31)	2.19
ianming Lu (2011)	0.77 (0.19, 3.19)	1.40
Ping Huang (2000)	0.63 (0.36, 1.10)	7.70
Ving Wang (2002)	0.19 (0.04, 0.79)	
ixin Gu (2003)	0.37 (0.04, 3.24)	
Youjuan Jiang (1997)	0.10 (0.01, 1.70)	
(ianli Bai (2005)	0.62 (0.26, 1.47)	
Chang Liu (2011)	(Excluded)	0.00
Subtotal (I-squared = 37.1%, p = 0.042)	0.45 (0.35, 0.58)	
Overall (I-squared = 26.7%, p = 0.076)	0.50 (0.41, 0.60)	100.00
i	10000	
.00198 1	506	

Figure 8. Forest plot of comparison: elemene versus other medications, outcome: gastrointestinal adverse reactions.

with moderate risk of bias. Though most of the included studies are RCTs, few of them reported details of randomization, blinding, indicating potential selection and detection bias may exist. Besides, the number of sample varies across studies. Second, though there is no significant heterogeneity across these eligible studies, the characteristics of patients and study design are different. All the included studies did not report the overall survival rate, making the total survival of patients with malignant pleural effusion still inconclusive. These inherent differences may increase the risk of bias. Overall, the findings of our meta-analysis are reliable, but it should be carefully viewed.

In conclusion, the results of this study show that elemene treatment can improve clinical control of malignant pleural effusion, QOL, with tolerable adverse events. Large scale, randomized, controlled, clinical trials are required to verify our findings.

#### Author contributions

Conceptualization: Dong-sheng Zhou. Data curation: Dong-sheng Zhou. Formal analysis: Ze-lin Zhang, Jian Liang. Methodology: Qing-tao Wang, Ze-lin Zhang. Project administration: Jun Li. Resources: Jian Liang. Software: Jun Li. Supervision: Hui Xiong.

Validation: Ya-fei Wang.

Writing – original draft: Qing-tao Wang, Jian Liang.

Writing – review & editing: Ze-lin Zhang.

#### References

- Porcel JM, Sole C, Salud A, et al. Prognosis of cancer with synchronous or metachronous malignant pleural effusion. Lung 2017;195:775–9.
- [2] Gadewad N, Deokar K, Ghorpade S. clinical profile of patients presenting with malignant pleural effusion to a tertiary health care centre. J Assoc Phys India 2017;65:28–31.
- [3] Penz E, Watt KN, Hergott CA, et al. Management of malignant pleural effusion: challenges and solutions. Cancer Manag Res 2017;9:229–41.
- [4] Amin Z, Iskandar SD, Sibli . Prognostic factors of 30-day survival of patients with malignant pleural effusion. Indian J Palliat Care 2017; 23:321–4.
- [5] Abrao FC, Peixoto RD, de Abreu IR, et al. Prognostic factors in patients with malignant pleural effusion: Is it possible to predict mortality in patients with good performance status. J Surg Oncol 2016;113:570–4.
- [6] Fitzgerald DB, Koegelenberg CFN, Yasufuku K, et al. Surgical and nonsurgical management of malignant pleural effusions. Expert Rev Respir Med 2017;1:15–26.
- [7] Abrao FC, Abreu IR, Cavalcanti MG, et al. Use of indwelling pleural catheters for the definitive treatment of malignant pleural effusion. J Bras Pneumol 2017;43:14–7.
- [8] Chen J, Chen YJ, Wu MD. Herbal extract elemene intrathoracic injection in the treatment of lung cancer patients with malignant pleural effusion: a meta-anaylsis. J Cancer Res Ther 2014;10(suppl 1):56–9.
- [9] Jiang Z, Jacob JA, Loganathachetti DS, et al. beta-elemene: mechanistic studies on cancer cell interaction and its chemosensitization effect. Front Pharmacol 2017;8:105.
- [10] Yu X, Xu M, Li N, et al. Beta-elemene inhibits tumor-promoting effect of M2 macrophages in lung cancer. Biochem Biophys Res Commun 2017;490:514–20.
- [11] Dong K, Wang S. Short-term efficacy of pleural cavity drainage and infusion of elemene combined with cisplatin in the treatment of malignant pleural effusion of lung cancer. Chin Clin J 2016;44:60–2.
- [12] Wang X, Wang H, Li L. A meta-analysis of elemene versus DDP intrapleural injection in the treatment of malignant pleural effusion caused by lung cancer. J Cancer Res Ther 2016;12:C244–7.
- [13] Higgins J., Green S. Cochrane handbook for systematic reviews of interventions Version 5.1. 0. The Cochrane Collaboration. Confidence intervals. 2011.
- [14] Jin-na W, Jin Q, Lei Z. Analysis of curative effect by elemene in the treatment of pleural effusion induced by lung cancer. Chin J Mod Drug Appl 2015;1:9.
- [15] Zhong J, Zhang D, Zhu Y. Clinical analysis of 96 cases of malignant pleural effusion treated with elemene. Med J Qilu 2011;26:551–2.
- [16] Ye A, Xia X. Clinical analysis of elemene emulsion in the treatment of pleural effusion. Hebei Med 2001;1:9.
- [17] Kong Y. Clinical analysis of thoracic cavity infusion of elemene in the treatment of malignant pleural effusion. ModMed Health 2012;28: 1521–2.
- [18] Sun J, Jiang B, Ren Y, et al. The clinical application of the treatment of malignant pleural effusion combined with the chest catheter perfusion. J Qigihar Univ Med 2014;665–6.
- [19] Lu J. Clinical observation of 30 cases of malignant pleural effusion treated by thoracic catheter drainage and infusion of elemene. Zhejiang J Tradit Chin Med 2011;46:422.
- [20] Wang H, Shi H, Jia M. Clinical observation of bleomycin and elemene in the treatment of non-small cell lung cancer complicated with pleural effusion. J Med Res 2007;36:108–9.
- [21] Fangfang S, Lijun D. Clinical observation of elemene and cisplatin pleural perfusion combined with hyperthermia in treatment of malignant pleural effusion. J Clin Med Pract 2015;19:89–91.
- [22] Chen S, Xie H. Clinical observation of elemene combined with interleukin-2 perfusion in the treatment of malignant pleural effusion of non-small cell lung cancer. Seek Med Ask Med 2012;10:820–1.
- [23] Wu B, Wang S, Zhang X. Clinical observation of elemene in the treatment of malignant pleural effusion of lung cancer. Guangzhou Med J 2015;46:74–6.
- [24] Liu C, Zhang H, Jia Z, et al. Clinical observation of elemene injection combined with cisplatin injection in the treatment of malignant pleural effusion. Mod J Integr Tradit Chin West Med 2011;1:12.

- [25] Li M. The clinical observation of malignant pleural effusion treated in elemenum emulsion. J Henan Univ Chin Med 2008;1:6.
- [26] Wang P, Wang M. Clinical observation of the treatment of malignant pleural and peritoneal effusion with elemene. J Bengbu Med Coll 2002;1:1.
- [27] Gao L, Ding J, Zhang Z. Clinical observation on 34 cases of malignant pleural effusion treated by endogenous hyperthermia combined with elemene. Zhejiang JTradit Chin Med 2013;1:48.
- [28] Yu J. Clinical observation on 142 cases of malignant pleural effusion treated by elemene injection combined with hyperthermia. Nei Mongol J Tradit Chin Med 2015;34:21.
- [29] Zhang Y, Hu T, Wang X, et al. Clinical observation on the treatment of malignant pleural effusion in the chest perfusion of elemene injection. Gansu Med J 2016;35:831–3.
- [30] Sun L. Clinical observation on treatment of lung cancer with malignant pleural effusion by elemene injection combined with intrapleural injection. Chin Commun Dr 2012;14:80.
- [31] Qi J, Zheng Y, Wang M. Clinical study of elemene for malignant chest effusion. J Mod Oncol 2011;1:12.
- [32] Chang L, Zhi-Ling J, LI W, et al. Clinical study of hyperthermia combined with intrathoracic drug injection to treat elderly patients with malignant pleural effusion. Geriatr Health Care 2011;17:293–5308.
- [33] Wu H, Chen P. Clinical study of intrapleural injection of elemene in the treatment of malignant pleural effusion. Guid Chin Med 2011;09: 165-6.
- [34] Zhihong F, Xiuhong N. Clinical study of intrapleural injection treatment for lung cancer with malignant pleural effusions. Pract J Cancer 2015; 30:1643–2555.
- [35] Li Z, Deng L, Zhou H. Clinical study on external application of chinese medicine combined with elemene injection pleural perfusion in treatment of malignant pleural effusion. Hubei J Tradit Chin Med 2016;38:10–1.
- [36] Li J. Clinical study on treatment of elderly patients with malignant pleural effusion by elemene combined with interleukin—2. Chin J Clin Ration Drug Use 2014;7:72–3.
- [37] Su J. Clinical study on treatment of malignant pleural effusion by elemene injection. Chin Foreign Med Treat 2014;1:9.
- [38] Wang A, Wang Y, Cui X. Comparison of clinical efficacy of elemene and bleomycin in the treatment of malignant pleural effusion. Strait Pharm J 2011;23:125–6.
- [39] Yang B, Weng F, Jin C. Comparison of the effects of elemene and cisplatin on cancerous pleural effusion. J Pract Oncol 2000;1:15.
- [40] Yong-hua H, Yu-fei F, Ding-gang L. Curative effect analysis of cisplatin and elemene combined with hyperthermia in the treatment of malignant pleural effusion. Chin Mod Med 2016;23:74–6.
- [41] Liu Z. The effect analysis of PLF combined with elemene on malignant pleural effusion. Clin Res Pract 2016;1:51–2.
- [42] Zhao F. Effect of bleomycin and elemene on thoracic effusion in pleural effusion. J Baotou Med Coll 2015;31:81–2.
- [43] Li Z, Zhang Y. Effect of elemene combined with chemotherapy on lung cancer with malignant pleural effusion. Chin J Misdiagn 2006;1:6.
- [44] Chen J, Zhong X, Wu X, et al. Efficacy of catheter drainage combined with elemene and cisplatin in the treatment of malignant pleural effusion. Chin J Clin Oncol 2004;1:31.
- [45] Li X. Efficacy of intrapleural injection of elemene and cisplatin in the treatment of malignant pleural effusion. Mod J Integr Tradit Chin West Med 2005;14:321–2.
- [46] Shi G. Efficacy of intrapleural injection of elemene in the treatment of malignant pleural effusion. J Pract Diagn Ther 2007;21:373–4.
- [47] Lian-ping J, Yue-di D, Li T, et al. Elemene, bleomycin, as well as the two drugs in the treatment of malignant pleural effusion clinical observation. Chin Oncol 2009;19:218–20.
- [48] Huang P. Injection of cisplatin and elemene in the treatment of malignant pleural effusion by closed drainage. J Youjiang Med Coll Natl 2000;1:6.
- [49] Yao X, Huang Y, Chen Z. Intrapleural injection of cisplatin or elemene in the treatment of malignant pleural effusion: a report of 60 cases. Guangxi Med J 2002;1636–7.
- [50] Wang Y, Xu N, Sun Z, et al. Observation of effect of elemene in treatment of non-small cell lung cancer combined with pleural effusion. Chin J Misdiagn 2009;9:
- [51] Lin S, Bai X. Observation on 46 cases of cancerous pleural effusion treated by elemene. Henan J Oncol 1996;267.
- [52] Wang L-d. Observation on the clinical efficacy of elemenum emulsion combined with intrapleural injection of low dose of cisplatin for the treatment of malignant pleural effusion in patients with lung cancer. J Clin Res 2012;29:1524–5.

- [53] Jiang Y, Ding H, Liu X, et al. Observation on the therapeutic effect of elemene cisplatin in the treatment of cancerous pleural effusion after closed drainage of thoracic cavity. JiangSu Med 1997;1:6.
- [54] Ling Z, Weijie Y, Weiqiang Z, et al. Radiofrequency hyperthermia combined with intraplearal infusion of elemene emulsion or staphylococcin in the treatment of malignant pleural effusion. Chin J Clin Med 2012;19:25–6.
- [55] Zhang J, Li H, Yu C. Short-term efficacy of intrapleural infusion of elemene and bleomycin in the treatment of malignant pleural effusion. Zhejiang Pract Med 2013;1:18.
- [56] Gao Y, Zhao W, Fu Q, et al. Therapeutic effect of elemene emulsion combined with cisplatin on malignant pleural effusion. J Hebei Med Univ 2010;31:1479–81.
- [57] Gu L, Fan F. Therapeutic effect of intra-thoracic injection of elemene emulsion on malignant pleural effusion. Mod J Integr Tradit Chin West Med 2003;12:708–9.
- [58] Li H, Zhang S, Sun J, et al. Treatment of 59 cases of malignant pleural effusion by intrapleural intra-tube heat irrigation combined with elemene and cisplatin. Chin Commun Phys 2007;28.
- [59] Zhou J, He LL, Ding XF, et al. Combinatorial antitumor effect of rapamycin and beta-elemene in follicular thyroid cancer cells. BioMed Res Int 2016;2016:1–8.
- [60] Xu XW, Yuan ZZ, Hu WH, et al. Meta-analysis on elemene injection combined with cisplatin chemotherapeutics in treatment of non-small cell lung cancer. Zhongguo Zhong Yao Za Zhi = Chin J Chin Mater Med 2013;38:1430–7.